Briacell Therapeutics Corp (BCTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $29.60M
Last updated: Nov 17, 2026 at 4:37 PM ET
Briacell Therapeutics Corp (BCTX) Stock Chart
Briacell Therapeutics (BCTX) has a latest price of $3.51 on Nov 17, 2026, 73.2% below its 52-week high of $13.09. Its price fell 61.7% over the past 12 months. The month-end price fell 100.0% over the 10 years through Oct 2026, a compound annual decline of 54.2%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $7,541.68 in Oct 2016 and its lowest $3.04 in Oct 2026, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart BCTX with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for BCTX.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 11.4%, and over 6 months it was flat. The month-end price fell 99.5% over the 3 years through Oct 2026, a compound annual decline of 83.2%.
| Period | Change |
|---|---|
| 1 month | +3.8% |
| 3 months | -11.4% |
| 6 months | 0.0% |
| 12 months | -61.7% |
| 12 months, with dividends | -61.7% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -99.5% | -83.2% |
| 5 years | -99.7% | -69.7% |
| 10 years | -100.0% | -54.2% |
Price by Year
Its best calendar year was 2021, when the price rose 98.6%, and its weakest was 2025, when it fell 91.6%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $3.04 | -57.2% |
| 2025 | $7.11 | -91.6% |
| 2024 | $84.71 | -90.3% |
| 2023 | $877.06 | +33.9% |
| 2022 | $655.17 | -47.2% |
| 2021 | $1,241.38 | +98.6% |
| 2020 | $625.19 | -54.1% |
| 2019 | $1,362.95 | -42.9% |
| 2018 | $2,385.17 | -47.5% |
| 2017 | $4,543.18 | -33.3% |
Trading Range
The price is 5.3% below its 50-day average of $3.71 and 6.5% below its 200-day average of $3.75.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $3.51 | |
| 52-week high | $13.09 | -73.2% |
| 52-week low | $2.60 | +35.0% |
| 50-day average | $3.71 | -5.3% |
| 200-day average | $3.75 | -6.5% |
Price Risk
Over 3 years, its largest fall from a peak was 99.7%.
| Measure | Value |
|---|---|
| 1-year beta | 1.57 |
| Largest fall, 1 year | -78.3% |
| Largest fall, 3 years | -99.7% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About BCTX
What is BCTX's 1-year price change?
Briacell Therapeutics's price fell 61.7% over the past 12 months. With dividends included, the 12-month total return was -61.7%.
What is BCTX's 5-year price change?
Briacell Therapeutics's month-end price fell 99.7% over the 5 years through Oct 2026, a compound annual decline of 69.7%. These figures leave out dividends.
What is BCTX's 52-week high and low?
Briacell Therapeutics's 52-week high is $13.09 and its 52-week low is $2.60. Its latest price of $3.51 on Nov 17, 2026 is 73.2% below the high.
What is BCTX's beta?
Briacell Therapeutics's 1-year beta against the S&P 500 is 1.57, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 78.3%.
Is the BCTX chart free?
Yes. Advanced Charting for BCTX is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
BCTX pages: Overview, Charting, Earnings, Financials, Statistics, Competitors